Protalix BioTherapeutics, Inc. (PLX) develops recombinant therapeutic proteins through its ProCellEx plant cell-based system and has reached commercial stage. With only one credible current analyst target available, there is no reliable multi-analyst average, so the $12 figure serves as a publicly referenced objective rather than a formal consensus.
That target originates from H.C. Wainwright, where the analyst reaffirmed a Buy rating and $12 price target on September 9, 2026, pointing to Elfabrio momentum and pipeline potential. The firm's history shows several downward revisions: $10 in November 2023, raised to $15 in February 2025, then cut to $12 in November 2025. Some data aggregators list an $11 average that appears to recycle the older $10 figure, but this does not reflect a second active analyst. In my view, the $12 target should be treated as one firm's perspective rather than broad Wall Street agreement. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The most recent verified share price sits near $2.53, roughly in the middle of a 52-week range spanning about $1.65 to $3.19. Reaching $12 would demand a gain of approximately 374%, an outsized move by any measure. With roughly 80.6 million shares outstanding, a $12 price would imply a market capitalization near $970 million, compared with about $204 million today—a re-rating on the order of four to five times.
Trailing-twelve-month revenue stands at approximately $80.6 million, with net income near $19 million and a price-to-earnings ratio of about 11, indicating the company is profitable yet still small. Any advance toward $12 would likely hinge on continued Elfabrio sales growth, milestone receipts, and successful progress with PRX-115 as it enters Phase 2 testing for uncontrolled gout.
PLX trades below its 52-week high of $3.19, with near-term resistance between $2.80 and $3.19 and support in the $2.30 to $2.60 zone. A decisive break above $3.19 would mark a notable technical step, yet the distance from that level to a double-digit target remains substantial, leaving limited durable structure to guide a move toward $12.
Analyst targets generally reflect a roughly 12-month research horizon, although H.C. Wainwright’s exact timeframe is not specified publicly. Investors should watch quarterly Elfabrio and Elelyso sales trends, data from the PRX-115 Phase 2 trial, any updates to 2026 guidance, and further revisions from analysts. The next earnings report is expected around mid-November 2026.
Can PLX reach $12? The target represents one analyst’s perspective rather than a broad consensus, and it would require a very large gain of roughly 374% from the current price near $2.53. The bull case centers on Elfabrio growth, milestone revenue, and the PRX-115 opportunity, while the bear case focuses on thin coverage, repeated target reductions, competitive and regulatory risk, and potential dilution. I’m watching this closely and believe investors should track upcoming earnings, Phase 2 progress, and any analyst updates before forming conclusions.
In my own research on thinly covered names like this, I often review Tickeron's AI Daily Buy/Sell Signals to monitor how market conditions and technical behavior are shifting. The platform applies artificial intelligence across thousands of stocks and ETFs to generate Buy, Sell, or Hold signals, which can complement traditional analysis when analyst input is limited. This helps me spot evolving trends more efficiently without replacing my own due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for PLX crossed bullishly above the 50-day moving average on November 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on PLX as a result. In 75 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PLX just turned positive on November 10, 2026. Looking at past instances where PLX's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
PLX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLX advanced for three days, in 207 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The 10-day RSI Indicator for PLX moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 28 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 32 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (3.596). P/E Ratio (10.583) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.697) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of recombinant therapeutic proteins
Industry Biotechnology